Guideline

Tetanus Prophylaxis in Wound Management

<table>
<thead>
<tr>
<th>Document ID</th>
<th>Version no.</th>
<th>Approval date</th>
<th>Executive sponsor</th>
<th>Effective date</th>
<th>Author/custodian</th>
<th>Review date</th>
<th>Authorisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHQ-GDL-01023</td>
<td>5.0</td>
<td>01/12/2022</td>
<td>Executive Director Medical Services</td>
<td>01/12/2022</td>
<td>Queensland Specialist Immunisation Service</td>
<td>01/12/2025</td>
<td>Executive Director Clinical Services</td>
</tr>
<tr>
<td>Supersedes</td>
<td>4.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Applicable to All Children’s Health Queensland Staff

Purpose

This guideline is to aid in the prescription of tetanus prophylaxis for tetanus prone wounds in children and adolescents according to the Australian Government Department of Health Immunisation Handbook.

Scope

This guideline relates to Children’s Health Queensland (CHQ) staff involved in the assessment and treatment of tetanus prone wounds. Refer to the Australian Government Department of Health Immunisation Handbook (Tetanus) for more information.

This guideline is not intended to be a substitute for specific professional or clinical advice, or to replace consultation with senior staff, which should always be sort if clinically relevant.

This material is published by Children’s Health Queensland with the intention of providing a guideline for use at the Queensland Children’s Hospital (QCH). Anyone wishing to use this guideline outside of the QCH should refer to their local Medicines Advisory Committee before using.

Related documents

Procedures, Guidelines, Protocols

- Medicines and Poisons Act 2019 (MPA)
- CHQ-HMP Vaccination Program – Health Management Protocol
- CHQ-PROC-01000 Substance Management Plan (Medicines)
- CHQ-PROC-01039 Medication - Administration
- CHQ-PROC-01017 Adverse Drug Reaction – Documentation and Reporting
- CHQ-PROC-01001 Medication – Prescribing
- CHQ-GDL-63000 Management of Water-immersed Wound Infections in Children
Guideline

Definition of Tetanus Prone Wound

Any wound other than a clean, minor cut is ‘tetanus-prone.’ Tetanus may occur after a seemingly trivial injury and it is possible to have no obvious signs of injury.

Certain types of injuries can favour the growth of *Clostridium tetani*, including:

- compound fractures (fractures associated with a break in the skin),
- bite wounds,
- deep, penetrating wounds,
- wounds that contain foreign bodies (especially wood splinters),
- wounds that are complicated by pyogenic infections,
- wounds with extensive tissue damage (for example contusions or burns),
- any superficial wound that is obviously contaminated with soil, dust or horse manure (especially if topical disinfection is delayed more than four hours),
- reimplantation of an avulsed tooth, because the tooth undergoes minimal washing and cleaning to increase the likelihood of successful reimplantation, or
- depot injections, either subcutaneous or intradermal, in people who inject drugs.

Management of Tetanus Prone Wound

**ALERT**

Tetanus immunoglobulin and/or tetanus-containing vaccine should be administered via intramuscular route as soon as practically possible after the injury.

Antibiotics do not prevent or treat tetanus. All tetanus-prone wounds must be disinfected and, where appropriate, have surgical treatment.

Tetanus Prone Wound Prophylaxis

People who have a tetanus prone wound should receive tetanus immunoglobulin (TIG) for passive protection if either:

- they have not previously received three or more doses of a tetanus-containing vaccine, or
- there is doubt about their tetanus vaccination status, or
- they have a humoral immune deficiency, Human Immunodeficiency Virus (HIV) or immunocompromised
**Tetanus Immunoglobulin Administration**

Dose of tetanus immunoglobulin for tetanus prophylaxis:

- 250 International Units if 24 hours or less since injury,
- 500 International Units if more than 24 hours since injury,

Note: tetanus immunoglobulin dosage is not weight or age based

- Tetanus immunoglobulin provides immediate protection that lasts for 3 to 4 weeks.
- Tetanus immunoglobulin is to be prescribed as per CHQ-PROC-01001 Medication - Prescribing and administered in line with CHQ-PROC-01039 Medication - Administration.
- Patients receiving tetanus immunoglobulin should also receive a tetanus-containing vaccine at the same time in the opposite limb with a separate syringe (see Tetanus Vaccination); for infants under 6 weeks of age seek ID advice.
- Appropriate tetanus prophylaxis should be administered as soon as possible following a wound but should also be given to patients who present late for medical attention. TIG should be administered up to 21 days following the injury.

For more information on tetanus immunoglobulin see CHQ-WI-02924 Immunoglobulin: NHig, HB Ig, Tlg and Zlg (passive immunisation).

**Immunisation History Assessment**

The Australian Immunisation Register (AIR) is a national register that aims to record all vaccines given to all people in Australia. The AIR should be used to access an individual's immunisation record, and to ensure its accuracy. Other immunisation records such as documentation from previous immunisation providers, any printed record including Personal Health Record (e.g. Red Book), Immunisation History tab in ieMR, My Health Record available from The Viewer tab in ieMR and the Vaccination Information and Vaccine Administration System (VIVAS) should be reviewed. The AIR should be updated to support the accuracy of an individual's immunisation record. A Medicare immunisation medical exemption form should be completed for contraindicated vaccines online via PRODA.

**Tetanus Vaccination**

A primary course of tetanus containing vaccine is included on the National Immunisation Program (NIP) at 2, 4 and 6 months of age. Booster doses of tetanus-containing vaccine are included on the NIP at 18 months of age, 4 years of age and in Year 7 of schooling.

Patients less than 9 years of age who have received 3 or more doses of tetanus-containing vaccine as per the NIP are not recommended additional doses of tetanus containing vaccine; the exception to this is for those who are immunosuppressed or immunocompromised (seek Infectious Diseases Specialist advice).

**A tetanus containing vaccine is recommended for patients who have NOT:**

- completed a primary tetanus vaccination course (e.g. 3 dose course), OR
received a booster dose of tetanus-containing vaccine within the last 5 years or as per National Immunisation Program (NIP). See above for timing of NIP booster dose above.

For patients requiring a tetanus-containing vaccine:

- Completion of tetanus vaccination course is highly recommended.
- If vaccination is refused, this should be documented in the medical notes and signs and symptoms of tetanus explained.
- Patient should be provided written information of when next tetanus-containing vaccine is recommended (e.g. more than 5 years).

Tetanus Vaccines

- **Less than 10 years of age:** who are due a primary course or booster dose of tetanus-containing vaccine should be recommended a DTPa containing vaccine (e.g. Infanrix-IPV/Quadracel [DTPa-IPV] or Infanrix-Hexa [DTPa-IPV-Hib-HepB]).
  
  Note: Infanrix/Tripacel (DTPa) vaccine can be used for those due or overdue this vaccine as per the **NIP at 18 months of age**. Infanrix/Tripacel (DTPa) vaccine is not funded for use for catch-up or those choosing not to receive the recommended DTPa containing vaccine offered on the NIP.

- **10 years of age and over:** who are due a primary course or booster dose of tetanus-containing vaccine should be recommended a dTpa containing vaccine e.g. Boostrix/Adacel (dTpa) vaccine.
ALERT – use flowchart for those who are:

- Unvaccinated (excludes under 6 weeks – seek advice from ID)
- Not vaccinated as per NIP
- 9 years of age or older, previously vaccinated as per NIP

ALERT

- Please read Tetanus Vaccination prior to using this algorithm aid
- If due 18-month-old vaccine as per National Immunisation Program see Tetanus Vaccines

Flowchart 1 - Algorithm to Aid in the Prescription of Tetanus Wound Prophylaxis

**START HERE**

- Has the patient received 3 doses of tetanus containing vaccine?
  - Yes
  - Is the patient over 12 months of age?
    - Yes
    - Has the patient received 4 doses of a tetanus containing vaccine?
      - Yes
      - Have they received a tetanus containing vaccine in the last 5 years?
        - Yes
        - No booster required
        - No
        - No booster required
      - No
      - Yes
      - No booster required
    - No
    - No booster required
  - No
  - Patient recommended Tetanus Immunoglobulin (TIG)
    - For immunocompromised patients please contact Infectious Diseases Medical Team for individual advice as patient may also require Tetanus Immunoglobulin (TIG)
    - Commence immunisation catch up plan
    - No booster required
  - No booster required

- No
  - Is the patient under 10 years?
    - Yes
    - Has patient received the recommended doses of Hib & Hep B?
      - Yes
      - Infanrix-hexa® (DTPa+IPV+Hib+Hep B)
        - No booster required
      - No
      - No booster required
    - No
    - Boostrix® / Adacel® (dTpa)
      - Infanrix-IPV® / Quadracel® (DTPa+IPV)
        - Commence immunisation catch up plan
        - No booster required
    - Commence immunisation catch up plan
    - No booster required
Consultation

Key stakeholders who reviewed this version:

- Director, IMPS, Allergy/Immunology, Rheumatology, QCH
- Infectious Diseases Consultant, Queensland Specialist Immunisation Service (QSIS) Medical Lead, QCH
- Nurse Practitioner, QSIS, QCH
- Nurse Practitioner, Emergency Department, QCH
- Senior Clinical Pharmacist team – Immunisation, QSIS, QCH
- Director of Pharmacy, QCH
- Clinical Pharmacist Lead - Antimicrobial Stewardship, QCH
- Nurse Manager, Blood Management, QCH
- Senior Medical Officer, Paediatric Emergency Medicine, QCH

Definition of terms

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
<th>Tetanus containing vaccine brands</th>
</tr>
</thead>
</table>
| DTPa | Child dose: Diphtheria, tetanus, pertussis | Infanrix-IPV® or Quadracel® (DTPa+IPV)  
Infanrix-Hexa® (DTPa+IPV+Hib+Hep B)  
Infanrix® (DTPa) |
| dTpa | Adult dose: Diphtheria, tetanus, pertussis | Boostrix® (dTpa)  
Adacel® (dTpa) |
| Hep B | Hepatitis B | Infanrix-Hexa® (DTPa+IPV+Hib+Hep B) |
| Hib | H. influenzae type b | Infanrix-Hexa® (DTPa+IPV+Hib+Hep B) |
| IPV | Inactivated polio vaccine | Infanrix-IPV® or Quadracel®(DTPa+IPV) |
| TIG | Tetanus Immunoglobulin | Tetanus Immunoglobulin |

References and suggested reading

2. Australian Government Department of Health - Questions about vaccination
3. National Centre for Immunisation Research & Surveillance (NCIRS)
4. NCIRS - SKAI Project: Sharing Knowledge About Immunisation
5. Australian Government Department of Health Immunisation Handbook online - Fundamentals of Immunisation
## Guideline revision and approval history

<table>
<thead>
<tr>
<th>Version No.</th>
<th>Modified by</th>
<th>Amendments authorised by</th>
<th>Approved by</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>Andrew Paton</td>
<td>Executive Director Medical Services</td>
<td>General Manager Operations</td>
</tr>
<tr>
<td>2.0 05/08/2016</td>
<td>Nurse Practitioner, Immunisation; and Pharmacist</td>
<td>Executive Director Medical Services</td>
<td>Executive Director Clinical Services (QCH)</td>
</tr>
<tr>
<td>3.0 28/0/2019</td>
<td>Nurse Practitioner, Immunisation; and Pharmacist</td>
<td>Executive Director Medical Services</td>
<td>Executive Director Clinical Services (QCH)</td>
</tr>
<tr>
<td>4.0 25/10/2019</td>
<td>Nurse Practitioner, Senior Medical Officer</td>
<td>Medical Director, Division of Medicine</td>
<td>Executive Director Clinical Services (QCH)</td>
</tr>
<tr>
<td>5.0 21/10/2022</td>
<td>Senior Pharmacist – Immunisation</td>
<td>Queensland Specialist Immunisation Service (QSIS)</td>
<td>A/Divisional Director Medicine</td>
</tr>
</tbody>
</table>

### Keywords
- Immunisation, prescribing, tetanus, vaccination, vaccine, wound management, Prophylaxis, 01023

### Accreditation references
- NSQHS Standards (1-8): 3 Preventing and controlling healthcare associated infections and 4 Medication Safety